Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT US

Editas Medicine, Inc.USUnited States Composite

7.42

USD
-0.02
(-0.27%)
Editas Medicine, Inc.
EDIT
(United States Composite)

Recent

price

7.42

P/E

ratio

-3.68

div

yld

- -

ROIC.AI

Business
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company News

  • Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update

  • Vertex's stock heads for all-time high as non-opioid painkiller shows promise

  • Editas Medicine Strikes License Deal With Vertex Pharmaceuticals

  • Editas Medicine Shares Climb 20% on 3Q Revenue Growth, Narrower Loss

  • Editas Medicine 3Q Loss/Shr 55c >EDIT

  • Editas Medicine Shares Jump After Stifel Turns Bullish

  • Geron Taps Michelle Robertson to Succeed Olivia Bloom as Finance Chief

  • Editas Medicine 2Q Loss/Shr 56c >EDIT

  • Gene Editing Is Working. Wall Street Is Taking Notice.

  • Editas Medicine Shares Fall 15% on Pricing of Secondary Stock Offering

  • Stocks to Watch: Ammo, Editas Medicine

  • Editas Medicine Shares Sink 5.7% after Secondary Stock Offering

  • Editas Medicine: Announces Appointment of Erick J. Lucera as Chief Fincl Officer >EDIT

  • Editas Medicine 1Q Loss/Shr 71c >EDIT

  • Editas Medicine Gets Orphan Drug Designation for EDIT-301

  • Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy

  • Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy

  • Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

  • Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists

  • Gene-Editing Start-Ups Are Being Courted. Big Pharma Senses a Buying Opportunity.